The increasing adoption of targeted therapies is expected to shift the market dynamics, owing to their robust effectiveness in the treatment of prostate cancer.For instance, in 2015, targeted therapies such as Xofigo reported YoY growth of 37% worldwide, indicating a growing acceptance among physicians.Novel hormonal therapies such as Xtandi and Zytiga continue to dominate the market, due to their effectiveness in treating metastatic castration-resistant prostate cancer (mCRPC). For instance, Xtandi reported YoY growth of 79.25% in 2015,reflecting an increase in the adoption rates.In this report, Technavio covers the present scenario and growth prospects of the

global prostate cancer drugs market for 2016-2020.

PART 01: Executive summary 7

Highlights 7

PART 02: Scope of the report 8

Market overview 8

Top-vendor offerings 9

PART 03: Market research methodology 11

Research methodology 11

Economic indicators 11

PART 04: Introduction 12

Key market highlights 12

PART 05: Disease overview 14

Understanding disease 14

Types of prostate cancer 15

Diagnosis 15

Key buying criteria 16

PART 06: Pipeline analysis 19

PART 07: Market landscape 28

Global prostate cancer therapeutics market 28

Five forces analysis 33

PART 08: Market segmentation by therapy 34

Hormonal therapy 35

Chemotherapy 35

Immunotherapy 36

Targeted therapy 36

PART 09: Geographical segmentation 37

Global prostate cancer drugs market by geographical

segmentation 2015-2020 37

Prostate cancer drugs market in Americas 39

Prostate cancer drugs market in EMEA 40

Prostate cancer drugs market in APAC 42

PART 10: Market drivers 45

Physicians preference toward adopting hormonal

therapies 45

Development of drugs with novel mechanism of action 46

Availability of large patient pool 46

PART 11: Impact of drivers 48

PART 12: Market challenges 49

Presence of alternative treatment approaches 49

High cost of drugs 50

Adverse side-effects of drugs 51

PART 13: Impact of drivers and challenges 53

PART 14: Market trends 54

PART 15: Vendor landscape 58

Competitive scenario 58

PART 16: Key vendor analysis 64

Johnson & Johnson 64

Astellas Pharma 67

AstraZeneca 71

Sanofi 76

AbbVie 80

Other prominent vendors 84

PART 17: Appendix 89

List of abbreviations 89

PART 18: Explore Technavio 90